A Study of KC1036 in Patients with Advanced Thymic Tumors
A phase 2 trial of KC1036 in thymoma and thymic carcinoma, run by Beijing Konruns Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of KC1036 in Patients with Advanced Thymic Tumors is a phase 2 interventional study registered as NCT05683886 by Beijing Konruns Pharmaceutical Co., Ltd., with 30 participants planned, started 2023-02-22 and due to reach its primary completion in 2025-02. Interventions recorded: KC1036.
Setting
A Single-arm, Open, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of KC1036 in the Patients with Advanced Recurrent or Metastatic Thymic Tumors
Phase
Phase 2
Sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Registry
Enrolled
30
Similar pages
not linked directly; found by shared links- TrialKC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Shares Beijing Konruns Pharmaceutical, KC1036 and the tag pipeline.
- TrialA Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Shares Beijing Konruns Pharmaceutical, KC1036.
- TrialSacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Shares Thymoma and thymic carcinoma and the tag pipeline.
- TrialA Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
Shares Beijing Konruns Pharmaceutical, KC1036.
- TreatmentEB-CAR30-NK
Shares Thymoma and thymic carcinoma and the tag pipeline.
- TrialTarget-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Shares Thymoma and thymic carcinoma and the tag pipeline.